Search | Clinical Trials Finder

Conditions: Neurobehavioral Components of Reward and Loss Valuation
Interventions: cognitive behavioral therapy, valuation with instruction, valuation without instruction; Behavioral
Lead sponsor: Virginia Polytechnic Institute and State University; Other
Eligibility: 25 Years to 50 Years
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Roanoke, Virginia

Conditions: Sudden Unexplained Death Syndrome, Sudden Unexplained Death in Childhood
Interventions: Biospecimin Collection; Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 11 Months to 100 Years
Enrollment: 1,600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Dry Eye
Interventions: Determine the ability of the iTrace™, BOSA™, OPD-Scan III, and IDRA to detect tear film stability utilizing Miebo®; Drug
Lead sponsor: Vance Thompson Vision; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Sioux Falls, South Dakota

Conditions: Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions: Biospecimen Collection, Cell-free Circulating Tumor DNA Assay, Computed Tomography, Docetaxel, Lutetium Lu 177 Vipivotide Tetraxetan, PSMA PET Scan, Single Photon Tomography and Computed Tomography Scan; Procedure · Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older · Male only
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: CT, Coronary Artery Disease
Interventions: CT-guided PCI, Routine PCI; Procedure
Lead sponsor: Minneapolis Heart Institute Foundation; Other
Eligibility: 22 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Crohn's Disease (CD)
Interventions: IOUS-guided margin selection; Device
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Obesity
Interventions: Biospecimen collection; Other
Lead sponsor: CorEvitas; Network
Eligibility: 18 Years and older
Enrollment: 10,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2099
U.S. locations: 1
States / cities: Waltham, Massachusetts

Conditions: Myxoid Liposarcoma, Round Cell Liposarcoma, Synovial Sarcoma
Interventions: Biospecimen Collection, Computed Tomography, Leukapheresis, Magnetic Resonance Imaging, Nogapendekin Alfa Inbakicept, X-Ray Imaging; Procedure · Biological
Lead sponsor: Seth Pollack; Other
Eligibility: 18 Years to 80 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Colorectal Cancer, High Risk Patients, Regorafenib
Interventions: Lorigerlimab, Regorafenib (CT); Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Basal Ganglia Diseases, Brain Diseases, Central Nervous System Diseases, Cerebral Disorder, Genetic Predisposition, Nervous System Diseases, Neurodegenerative Diseases, Parkinson Disease, Parkinsonian Disorders, Prodromal Stage, Synucleinopathies
Interventions: Increase of physical activity volume and intensity with the use of a motivational smartphone application; Behavioral
Lead sponsor: Radboud University Medical Center; Other
Eligibility: 50 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Acute Myeloid Leukemia
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Cytarabine, Echocardiography Test, Hydroxyurea, Leukapheresis, Multigated Acquisition Scan, Questionnaire Administration, Ziftomenib; Procedure · Drug · Other
Lead sponsor: Uma Borate; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Depression
Interventions: Brief Behavioral Therapy for Insomnia, Electroencephalography (EEG), Propofol; Behavioral · Diagnostic Test · Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 60 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Breast Cancer, Gastrointestinal Cancer, Hepatocellular Carcinoma, Lung Cancer, Ovarian Cancer, Pancreas Cancer, Prostate Cancer, Renal Cell Carcinoma, Urothelial Carcinoma
Interventions: QXL138AM Injection every 2 weeks by IV Infusion; Biological
Lead sponsor: Nammi Therapeutics Inc; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 10
States / cities: Los Angeles, California • Newport, California • Denver, Colorado + 5 more

Conditions: Atypical Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic/Myeloproliferative Neoplasm, Recurrent Myelodysplastic/Myeloproliferative Neoplasm, Recurrent Myeloproliferative Neoplasm, Refractory Chronic Myelomonocytic Leukemia, Refractory Myelodysplastic/Myeloproliferative Neoplasm, Refractory Myeloproliferative Neoplasm
Interventions: Axatilimab, Azacitidine, Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Survey Administration; Biological · Drug · Procedure + 1 more
Lead sponsor: Uma Borate; Other
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Cervical Carcinoma, Fallopian Tube Carcinoma, Malignant Solid Neoplasm, Malignant Uterine Neoplasm, Ovarian Carcinoma, Primary Peritoneal Carcinoma, Vulvar Carcinoma
Interventions: Best Practice, Cilostazol, Cryocompression Therapy, Paclitaxel, Quality-of-Life Assessment; Other · Drug · Device
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 3
States / cities: Atlanta, Georgia

Conditions: Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma, Ann Arbor Stage III Follicular Lymphoma, Ann Arbor Stage III Marginal Zone Lymphoma, Ann Arbor Stage IV Follicular Lymphoma, Ann Arbor Stage IV Marginal Zone Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma
Interventions: Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Mosunetuzumab, Positron Emission Tomography, Questionnaire Administration; Procedure · Biological · Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Peripheral Arterial Disease
Interventions: Golazo® Peripheral Atherectomy System (Golazo® Peripheral AS); Device
Lead sponsor: Nipro Vascular Innovations Americas, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 20
States / cities: Scottsdale, Arizona • Merced, California • Fort Lauderdale, Florida + 16 more

Conditions: Aging, HIV
Interventions: Customized activity plan, Customized nutrition plan; Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 50 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Survivorship
Interventions: Behavioral Activation, Supportive Psychotherapy; Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 65 Years and older
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: APC Gene Mutation, ATM Gene Mutation, BARD1 Gene Mutation, BMPR1A Gene Mutation, BRCA1 Mutation, BRCA2 Mutation, BRIP1 Gene Mutation, CDKN2A Mutation, CHEK2 Gene Mutation, EPCAM Gene Mutation, GREM1, MLH1 Gene Mutation, MSH2 Gene Mutation, MSH6 Gene Mutation, PALB2 Gene Mutation, PMS2 Gene Mutation, POLD1 Gene Mutation, POLE Gene Mutation, PTEN Gene Mutation, RAD51C Gene Mutation, RAD51D Gene Mutation, SMAD4
Interventions: Intervention Arm At-risk Relative/ARR Contacts, MyGene Portal, Standard of Care; Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 25 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 8
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: HER2-positive Advanced Solid Tumor
Interventions: DB-1303/BNT323, Itraconazole, Pertuzumab Injection, Ritonavir; Biological · Drug
Lead sponsor: DualityBio Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 796 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 35
States / cities: Cerritos, California • Los Angeles, California • San Diego, California + 29 more

Conditions: Mucosal Melanoma of the Head and Neck
Interventions: Hypofractionated radiation therapy, Pembrolizumab; Radiation · Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 16 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2032
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Alcohol Use Disorder (AUD)
Interventions: Alcohol Cue Reactivity Paradigm; Behavioral
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 21 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Tinnitus, Tinnitus Aggravated, Tinnitus, Subjective
Interventions: neurofeedback-guided brain connectivity modulation, sham neurofeedback-guided brain connectivity modulation; Behavioral
Lead sponsor: University of Illinois at Urbana-Champaign; Other
Eligibility: 18 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Urbana, Illinois

Search by objective public record fields.

Valuation in Depressed Mood, Anhedonia, and Anxiety

Sudden Unexplained Death in Childhood (SUDC) Registry

BL-RX01-TFSTAB-1402

Measuring Circulating Tumor Deoxyribonucleic Acid Tumor Fraction to Guide Early 177Lu-PSMA-617 Treatment Discontinuation in Patients With Metastatic Castration-Resistant Prostate Cancer, DYNAMO Trial

Coronary Computed Tomography Angiography (CCTA) for the Pre-procedural Planning of Percutaneous Coronary Intervention

Ultrasound-Guided Versus Standard Margin Selection in Ileocecal Resection of Terminal Ileal CD

PPDTM CorEvitasTM Obesity (OBR) Drug Effectiveness and Safety Registry

N-803 in Patients With Progressive Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Previously Treated With Adoptive Cellular Therapy

Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial]

Slow-SPEED: Slowing Parkinson's Early Through Exercise Dosage

Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy

Slow Wave Induction by Propofol to Eliminate Depression (SWIPED) Stage II

Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma

Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia

Cryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients With Gynecological Cancers

Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma

The Golazo® Peripheral Atherectomy System for a Safe and Effective Atherectomy (GREAT Trial)

Identifying Challenges to Healthy Aging in Persons With Human Immunodeficiency Virus (HIV) Age 50 and Older

A Study of Brief Behavioral Activation for the Treatment of Depression in Older Adult Cancer Survivors

An Intervention to Increase Genetic Testing in Families Who May Share a Gene Mutation Related to Cancer Risk and An Intervention to Help Patients and Their Primary Care Providers Stay Up-to-date About Uncertain Genetic Test Results

A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors

Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma

Sensory and Physical Reactions to Beverage Cues

Non-Invasive Neurofeedback Training to Alleviate Tinnitus Distress